# OnCo record codebreak-100 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/codebreak-100/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "codebreak-100", "NCT03600883" ;
  schema:name "CodeBreaK 100 (pancreatic cancer cohort)"@en ;
  schema:alternateName "CodeBreaK100"@en, "CodeBreak 100"@en, "AMG 510 phase 1/2"@en ;
  schema:description "CodeBreaK 100 gave the first KRAS inhibitor to 38 people whose pancreatic cancer carried the rare G12C mutation and had progressed after chemotherapy; one in five tumours shrank and patients lived a median 6.9 months, proof that KRAS can be drugged in this disease even though the target is uncommon here."@en ;
  schema:url <https://onco.cc/trials/codebreak-100/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03600883>, <https://doi.org/10.1056/NEJMoa2208470>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22LUMAKRAS%22> ;
  onco:status "positive" ;
  onco:phase "1/2" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/kras-g12c-pdac/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/sotorasib/> ;
  onco:companies <https://onco.cc/companies/amgen/> ;
  onco:terms <https://onco.cc/terms/kras-mutation-subtypes/> ;
  onco:trials <https://onco.cc/trials/nct03785249/>, <https://onco.cc/trials/rasolute-302/> ;
  onco:people <https://onco.cc/people/john-strickler/> .